Peptide opioids and morphine effects on inflammatory process.
Morphine was found to inhibit human granulocyte aggregation and ATP, thromboxane B2 (TxB2), and leukotriene B4 (LTB4) secretion during cell aggregation. None of the opioid peptides tested [(D-Ala2, D-Leu5)-enkephalin (DADL), (D-Ala2, N-Me-Phe4, Gly-ol5)-enkephalin (DAGO) or dynorphin 1-9 (Dyn 1-9)] was capable of mimicking morphine effects, while Dyn 1-9 per se induced TxB2 and LTB4 secretion from granulocytes. Morphine inhibition of both cell aggregation and ATP, but not of arachidonic acid metabolism product secretion, was prevented by naloxone. The naloxone-sensitive impairment by morphine of CD11b-CD18 complex surface expression observed could play a role in opioid inhibition of granulocyte activation.
Mazzone
A
A
Department of Internal Medicine and Therapeutics, University of Pavia, IRCCS San Matteo Hospital, Italy.
Ricevuti
G
G
Pasotti
D
D
Fioravanti
A
A
Marcoli
M
M
Lecchini
S
S
Notario
A
A
Frigo
G M
GM
D000255:Adenosine Triphosphate / Q000378:metabolism; D000943:Antigens, Differentiation / Q000032:analysis; D018845:CD11 Antigens; D018821:CD18 Antigens; D002449:Cell Aggregation / Q000187:drug effects; D003864:Depression, Chemical; D004723:Endorphins / Q000494:pharmacology*; D006801:Humans; D007975:Leukotriene B4 / Q000378:metabolism; D009020:Morphine / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D016028:Receptors, Leukocyte-Adhesion / Q000032:analysis; D013929:Thromboxane B2 / Q000378:metabolism
D000943:Antigens, Differentiation; D018845:CD11 Antigens; D018821:CD18 Antigens; D004723:Endorphins; D016028:Receptors, Leukocyte-Adhesion; D007975:Leukotriene B4; D009270:Naloxone; D013929:Thromboxane B2; D009020:Morphine; D000255:Adenosine Triphosphate